For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

The response rate difference versus placebo was 25.6% and 31.6%, respectively, for ivarmacitinib 4 mg and 8 mg, with no reported deaths, thromboembolic events, or major cardiovascular events.

Microdosing, or low-dose treatment of psychedelics such as lysergic acid diethylamide (LSD), has gained popularity in recent ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in agriculture and horticulture. They were developed by researchers at the Martin ...

Compared with AI-drafted messages, human-drafted medical communications scored a mean of 0.30, 0.28, and 0.43 points lower in terms of patient satisfaction, usefulness, and perception they were cared ...